Abstract
Autoimmune diabetes is a disease characterized by the selective destruction of insulin-secreting β-cells of the endocrine pancreas by islet-reactive T cells. Autoimmune disease requires a complex interplay between host genetic factors and environmental triggers that promote the activation of such antigen-specific T lymphocyte responses. Given the critical involvement of self-reactive T lymphocyte in diabetes pathogenesis, understanding how these T lymphocyte populations contribute to disease is essential to develop targeted therapeutics. To this end, several key antigenic T lymphocyte epitopes have been identified and studied to understand their contributions to disease with the aim of developing effective treatment approaches for translation to the clinical setting. In this review, we discuss the role of pathogenic islet-specific T lymphocyte responses in autoimmune diabetes, the mechanisms and cell types governing autoantigen presentation, and therapeutic strategies targeting such T lymphocyte responses for the amelioration of disease.
Original language | English (US) |
---|---|
Article number | 1440045 |
Journal | Frontiers in immunology |
Volume | 15 |
DOIs | |
State | Published - 2024 |
Bibliographical note
Publisher Copyright:Copyright © 2024 Dwyer, Shaheen and Fife.
Keywords
- T cells
- antigen specific therapy
- autoantigens
- autoimmune diabetes
- hybrid insulin peptides
PubMed: MeSH publication types
- Journal Article
- Review